Plasma levels of trastuzumab in gastric cancer : Case report
Introduction The use of trastuzumab with a fluoropyrimidine and platinum compound is currently the standard first-line treatment of patients with metastatic HER2-positive gastric cancer, but it appears that serum levels of trastuzumab determine the clinical effectiveness of this treatment, affecting progression-free survival and overall survival. Case report We report the case of a patient with metastatic HER2-positivegastric cancer, receiving XELOX (fluoropyrimidine and oxaliplatin) plus trastuzumab at standard doses, who presented sub-therapeutic serum levels during the first two treatment cycles and rapid disease progression (progression-free survival = 5.6 months). Discussion This case reveals a possible cause of poor effectiveness of trastuzumab treatment for metastatic gastric cancer in some patients, namely low circulating levels of the drug. It highlights the importance of monitoring as a possible tool for individual dose adjustment to optimize this therapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners - 23(2017), 8 vom: 23. Dez., Seite 635-637 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
González-García, J [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antineoplastic Agents, Immunological |
|---|
| Anmerkungen: |
Date Completed 06.07.2018 Date Revised 02.12.2018 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1177/1078155216670228 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM264655028 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM264655028 | ||
| 003 | DE-627 | ||
| 005 | 20231224210555.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1177/1078155216670228 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0882.xml |
| 035 | |a (DE-627)NLM264655028 | ||
| 035 | |a (NLM)27664112 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a González-García, J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Plasma levels of trastuzumab in gastric cancer |b Case report |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.07.2018 | ||
| 500 | |a Date Revised 02.12.2018 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Introduction The use of trastuzumab with a fluoropyrimidine and platinum compound is currently the standard first-line treatment of patients with metastatic HER2-positive gastric cancer, but it appears that serum levels of trastuzumab determine the clinical effectiveness of this treatment, affecting progression-free survival and overall survival. Case report We report the case of a patient with metastatic HER2-positivegastric cancer, receiving XELOX (fluoropyrimidine and oxaliplatin) plus trastuzumab at standard doses, who presented sub-therapeutic serum levels during the first two treatment cycles and rapid disease progression (progression-free survival = 5.6 months). Discussion This case reveals a possible cause of poor effectiveness of trastuzumab treatment for metastatic gastric cancer in some patients, namely low circulating levels of the drug. It highlights the importance of monitoring as a possible tool for individual dose adjustment to optimize this therapy | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Trastuzumab | |
| 650 | 4 | |a gastric cancer | |
| 650 | 4 | |a pharmacokinetics | |
| 650 | 7 | |a Antineoplastic Agents, Immunological |2 NLM | |
| 650 | 7 | |a Receptor, ErbB-2 |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a Trastuzumab |2 NLM | |
| 650 | 7 | |a P188ANX8CK |2 NLM | |
| 700 | 1 | |a Alonso-Alvarez, B |e verfasserin |4 aut | |
| 700 | 1 | |a Nazco-Casariego, G J |e verfasserin |4 aut | |
| 700 | 1 | |a Batista-López, N |e verfasserin |4 aut | |
| 700 | 1 | |a Guttiérrez-Nicolás, F |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners |d 1997 |g 23(2017), 8 vom: 23. Dez., Seite 635-637 |w (DE-627)NLM094530254 |x 1477-092X |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2017 |g number:8 |g day:23 |g month:12 |g pages:635-637 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1177/1078155216670228 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2017 |e 8 |b 23 |c 12 |h 635-637 | ||